Acorda plans 2nd-qtr regulatory filings for CVT-301 on positive new data

29 March 2017

US specialty pharma company Acorda Therapeutics (Nasdaq: ACOR) has released positive results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson’s disease.

The data that showed no differences in pulmonary function between the group receiving CVT-301 and an observational control cohort. These results are consistent with previously reported data from Phase IIb and Phase III clinical trials.

Acorda’s shares moved up 2.7% to $26.80 following the announcement. Last month, the stock leapt more than 25% to $23.55 when the company announced strong Phase III data for CVT-301.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK